Artelo Biosciences’ (ARTL) Buy Rating Reaffirmed at D. Boral Capital

D. Boral Capital reiterated their buy rating on shares of Artelo Biosciences (NASDAQ:ARTL) in a research note published on Monday,Benzinga reports. The brokerage currently has a $6.00 price target on the stock.

Other research analysts also recently issued reports about the company. EF Hutton Acquisition Co. I raised Artelo Biosciences to a “strong-buy” rating in a report on Tuesday, October 1st. HC Wainwright restated a “buy” rating and set a $5.00 target price on shares of Artelo Biosciences in a research note on Monday.

Artelo Biosciences Stock Performance

Shares of Artelo Biosciences stock opened at $1.16 on Monday. The company has a 50-day simple moving average of $1.14 and a two-hundred day simple moving average of $1.24. The stock has a market capitalization of $3.74 million, a PE ratio of -0.40 and a beta of 1.29. Artelo Biosciences has a 52-week low of $1.00 and a 52-week high of $1.75.

Artelo Biosciences (NASDAQ:ARTL) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.35) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.41) by $0.06. As a group, equities research analysts forecast that Artelo Biosciences will post -2.62 EPS for the current fiscal year.

Artelo Biosciences Company Profile

Artelo Biosciences, Inc, a clinical stage biopharmaceutical company, develops and commercializes therapeutics that target lipid-signaling pathways in the United States. It's product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment anxiety, post-traumatic stress disorder, epilepsy, inflammatory bowel disease, and other potential indications; and ART26.12, a fatty acid binding protein 5 inhibitor for treating chemotherapy induced peripheral neuropathy, diabetic neuropathy, prostate cancer and breast cancer, pain, dermatologic conditions, and anxiety disorders.